GlassScriptPhysician profile
Amanda M Chamberlin
NPI 1659538668
$2,673.57
in general payments reported to CMS, 2019-2025
30 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $572 · 2020: $238 · 2021: $404 · 2022: $478 · 2023: $410 · 2024: $216 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $982.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $494.72 | 2021-2025 | Synthroid, Vraylar, Ubrelvy |
| Pfizer INC. | $372.61 | 2019-2024 | |
| Novo Nordisk INC | $304.13 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $269.19 | 2019-2024 | Trelegy Ellipta, Pediarix, Bexsero |
| E.R. Squibb & Sons, L.L.C. | $199.14 | 2019-2024 | Eliquis |
| Abbott Laboratories | $120.05 | 2022-2023 | Freestyle Libre 3 |
| Medtronic, INC. | $106.47 | 2023-2025 | Inceptiv, Venaseal |
| Janssen Pharmaceuticals, INC | $99.83 | 2019-2022 | |
| Amgen INC. | $78.95 | 2025 | Repatha, Otezla |
| Lilly USA, LLC | $76.62 | 2021-2025 | Mounjaro |
| Astellas Pharma US INC | $72.02 | 2022-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $61.27 | 2022-2023 | |
| Stryker Corporation | $50.91 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S, Clottriever Bold Catheter |
| Allergan, INC. | $43.59 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $39.05 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $35.19 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.48 | 2022-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.19 | 2020-2023 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $23.85 | 2023 | Rexulti |
| Exact Sciences Corporation | $23.30 | 2023 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.40 | 2025 | Caplyta |
| Apria Healthcare LLC | $17.12 | 2021 | |
| Antares Pharma, INC. | $16.10 | 2022 | |
| Shield Therapeutics INC | $15.85 | 2024 | |
| Supernus Pharmaceuticals, INC. | $15.12 | 2024 | Qelbree |
| Astrazeneca Pharmaceuticals LP | $14.57 | 2025 | Farxiga |
| Merck Sharp & Dohme LLC | $14.20 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.00 | 2022 | |
| Daiichi Sankyo INC. | $12.85 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Chamberlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.